Do analysts prefer DRCT or SLGL?

Sol-Gel Technologies has a consensus price target of $197.50, indicating a potential upside of 166.86%. Given Sol-Gel Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Sol-Gel Technologies is more favorable than Direct Digital. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Direct Digital 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Sol-Gel Technologies 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67

Is SLGL or OCS more profitable?

Sol-Gel Technologies has a net margin of -5.66% compared to Oculis' net margin of -8,460.67%. Sol-Gel Technologies' return on equity of -3.17% beat Oculis' return on equity. Company Net Margins Return on Equity Return on Assets Sol-Gel Technologies -5.66% -3.17% -2.58% Oculis -8,460.67% -56.78% -45.62%

Does the media prefer SLGL or OCS?

In the previous week, Oculis had 1 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 4 mentions for Oculis and 3 mentions for Sol-Gel Technologies. Sol-Gel Technologies' average media sentiment score of 1.61 beat Oculis' score of 1.24 indicating that Sol-Gel Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sol-Gel Technologies 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Oculis 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SLGL or SPRY?

In the previous week, ARS Pharmaceuticals had 3 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 6 mentions for ARS Pharmaceuticals and 3 mentions for Sol-Gel Technologies. Sol-Gel Technologies' average media sentiment score of 1.61 beat ARS Pharmaceuticals' score of 0.31 indicating that Sol-Gel Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sol-Gel Technologies 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive ARS Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Sol-Gel Technologies (SLGL) Competitors

$74.01 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$74.32 +0.31 (+0.43%)

As of 07/2/2026 07:39 PM Eastern

Compare

SLGL vs. DRCT, TRAW, ESPR, OCS, and SPRY

Should you buy Sol-Gel Technologies stock or one of its competitors? MarketBeat compares Sol-Gel Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sol-Gel Technologies include Direct Digital (DRCT), Traws Pharma (TRAW), Esperion Therapeutics (ESPR), Oculis (OCS), and ARS Pharmaceuticals (SPRY).

How does Sol-Gel Technologies compare to Direct Digital?

Direct Digital (NASDAQ:DRCT) and Sol-Gel Technologies (NASDAQ:SLGL) are related small-cap companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

Sol-Gel Technologies has lower revenue, but higher earnings than Direct Digital. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Direct Digital, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Direct Digital	$34.69M	0.06	-$18.95M	-$201.62	N/A
Sol-Gel Technologies	$19.39M	10.73	-$6.13M	-$0.34	N/A

Sol-Gel Technologies has a net margin of -5.66% compared to Direct Digital's net margin of -65.75%. Direct Digital's return on equity of 0.00% beat Sol-Gel Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Direct Digital	-65.75%	N/A	-59.57%
Sol-Gel Technologies	-5.66%	-3.17%	-2.58%

Direct Digital has a beta of 5.32, meaning that its stock price is 432% more volatile than the broader market. Comparatively, Sol-Gel Technologies has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market.

Sol-Gel Technologies has a consensus price target of $197.50, indicating a potential upside of 166.86%. Given Sol-Gel Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Sol-Gel Technologies is more favorable than Direct Digital.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Direct Digital	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

4.0% of Direct Digital shares are owned by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are owned by institutional investors. 25.6% of Direct Digital shares are owned by company insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Direct Digital had 5 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 8 mentions for Direct Digital and 3 mentions for Sol-Gel Technologies. Sol-Gel Technologies' average media sentiment score of 1.61 beat Direct Digital's score of -1.00 indicating that Sol-Gel Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Direct Digital	Negative
Sol-Gel Technologies	Very Positive

Summary

Sol-Gel Technologies beats Direct Digital on 12 of the 17 factors compared between the two stocks.

How does Sol-Gel Technologies compare to Traws Pharma?

Traws Pharma (NASDAQ:TRAW) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

Traws Pharma currently has a consensus target price of $1.00, indicating a potential upside of 30.26%. Sol-Gel Technologies has a consensus target price of $197.50, indicating a potential upside of 166.86%. Given Sol-Gel Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Sol-Gel Technologies is more favorable than Traws Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Traws Pharma	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Traws Pharma has a beta of 1.51, indicating that its share price is 51% more volatile than the broader market. Comparatively, Sol-Gel Technologies has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

Traws Pharma has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -5.66%. Sol-Gel Technologies' return on equity of -3.17% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Traws Pharma	N/A	-913.18%	-133.88%
Sol-Gel Technologies	-5.66%	-3.17%	-2.58%

Traws Pharma has higher earnings, but lower revenue than Sol-Gel Technologies. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Traws Pharma	$2.79M	2.80	$9.17M	-$1.69	N/A
Sol-Gel Technologies	$19.39M	10.73	-$6.13M	-$0.34	N/A

8.0% of Traws Pharma shares are owned by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are owned by institutional investors. 7.6% of Traws Pharma shares are owned by insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Sol-Gel Technologies had 3 more articles in the media than Traws Pharma. MarketBeat recorded 3 mentions for Sol-Gel Technologies and 0 mentions for Traws Pharma. Sol-Gel Technologies' average media sentiment score of 1.61 beat Traws Pharma's score of 0.00 indicating that Sol-Gel Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Traws Pharma	Neutral
Sol-Gel Technologies	Very Positive

Summary

Sol-Gel Technologies beats Traws Pharma on 13 of the 17 factors compared between the two stocks.

How does Sol-Gel Technologies compare to Esperion Therapeutics?

Sol-Gel Technologies (NASDAQ:SLGL) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

Sol-Gel Technologies has higher earnings, but lower revenue than Esperion Therapeutics. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Esperion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sol-Gel Technologies	$19.39M	10.73	-$6.13M	-$0.34	N/A
Esperion Therapeutics	$403.14M	2.02	-$22.68M	-$0.06	N/A

Esperion Therapeutics has a net margin of 0.12% compared to Sol-Gel Technologies' net margin of -5.66%. Esperion Therapeutics' return on equity of -0.14% beat Sol-Gel Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sol-Gel Technologies	-5.66%	-3.17%	-2.58%
Esperion Therapeutics	0.12%	-0.14%	0.12%

Sol-Gel Technologies currently has a consensus target price of $197.50, suggesting a potential upside of 166.86%. Esperion Therapeutics has a consensus target price of $5.54, suggesting a potential upside of 75.32%. Given Sol-Gel Technologies' stronger consensus rating and higher possible upside, equities analysts clearly believe Sol-Gel Technologies is more favorable than Esperion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

26.2% of Sol-Gel Technologies shares are owned by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are owned by institutional investors. 66.5% of Sol-Gel Technologies shares are owned by company insiders. Comparatively, 1.6% of Esperion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Sol-Gel Technologies has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market. Comparatively, Esperion Therapeutics has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market.

In the previous week, Sol-Gel Technologies had 3 more articles in the media than Esperion Therapeutics. MarketBeat recorded 3 mentions for Sol-Gel Technologies and 0 mentions for Esperion Therapeutics. Esperion Therapeutics' average media sentiment score of 1.66 beat Sol-Gel Technologies' score of 1.61 indicating that Esperion Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Sol-Gel Technologies	Very Positive
Esperion Therapeutics	Very Positive

Summary

Sol-Gel Technologies beats Esperion Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Sol-Gel Technologies compare to Oculis?

Sol-Gel Technologies (NASDAQ:SLGL) and Oculis (NASDAQ:OCS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

In the previous week, Oculis had 1 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 4 mentions for Oculis and 3 mentions for Sol-Gel Technologies. Sol-Gel Technologies' average media sentiment score of 1.61 beat Oculis' score of 1.24 indicating that Sol-Gel Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sol-Gel Technologies	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Oculis	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sol-Gel Technologies has higher revenue and earnings than Oculis. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sol-Gel Technologies	$19.39M	10.73	-$6.13M	-$0.34	N/A
Oculis	$1.45M	564.61	-$119.44M	-$2.13	N/A

Sol-Gel Technologies has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, Oculis has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market.

Sol-Gel Technologies currently has a consensus target price of $197.50, indicating a potential upside of 166.86%. Oculis has a consensus target price of $38.33, indicating a potential upside of 171.48%. Given Oculis' stronger consensus rating and higher possible upside, analysts clearly believe Oculis is more favorable than Sol-Gel Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Sol-Gel Technologies has a net margin of -5.66% compared to Oculis' net margin of -8,460.67%. Sol-Gel Technologies' return on equity of -3.17% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sol-Gel Technologies	-5.66%	-3.17%	-2.58%
Oculis	-8,460.67%	-56.78%	-45.62%

26.2% of Sol-Gel Technologies shares are owned by institutional investors. Comparatively, 22.3% of Oculis shares are owned by institutional investors. 66.5% of Sol-Gel Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Sol-Gel Technologies beats Oculis on 11 of the 17 factors compared between the two stocks.

How does Sol-Gel Technologies compare to ARS Pharmaceuticals?

Sol-Gel Technologies (NASDAQ:SLGL) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Sol-Gel Technologies has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

In the previous week, ARS Pharmaceuticals had 3 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 6 mentions for ARS Pharmaceuticals and 3 mentions for Sol-Gel Technologies. Sol-Gel Technologies' average media sentiment score of 1.61 beat ARS Pharmaceuticals' score of 0.31 indicating that Sol-Gel Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sol-Gel Technologies	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
ARS Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sol-Gel Technologies has higher earnings, but lower revenue than ARS Pharmaceuticals. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sol-Gel Technologies	$19.39M	10.73	-$6.13M	-$0.34	N/A
ARS Pharmaceuticals	$84.28M	10.09	-$171.30M	-$2.01	N/A

Sol-Gel Technologies currently has a consensus price target of $197.50, suggesting a potential upside of 166.86%. ARS Pharmaceuticals has a consensus price target of $28.20, suggesting a potential upside of 229.44%. Given ARS Pharmaceuticals' higher possible upside, analysts clearly believe ARS Pharmaceuticals is more favorable than Sol-Gel Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

26.2% of Sol-Gel Technologies shares are held by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Sol-Gel Technologies has a net margin of -5.66% compared to ARS Pharmaceuticals' net margin of -200.00%. Sol-Gel Technologies' return on equity of -3.17% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sol-Gel Technologies	-5.66%	-3.17%	-2.58%
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%

Summary

Sol-Gel Technologies beats ARS Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

Get Sol-Gel Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLGL vs. The Competition

Export

Metric	Sol-Gel Technologies	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$207.96M	$6.20B	$7.18B	$12.47B
Dividend Yield	N/A	0.64%	2.67%	6.51%
P/E Ratio	-217.67	8.95	28.02	24.70
Price / Sales	10.73	24.74	534.82	99.70
Price / Cash	N/A	8.86	49.26	57.09
Price / Book	9.04	4.40	10.96	6.46
Net Income	-$6.13M	$99.67M	$3.57B	$337.01M
7 Day Performance	0.69%	1.55%	2.12%	1.69%
1 Month Performance	-5.09%	8.16%	5.25%	3.81%
1 Year Performance	901.49%	129.25%	33.29%	23.90%

Sol-Gel Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLGL Sol-Gel Technologies	4.1506 of 5 stars	$74.01 flat	$197.50 +166.9%	+901.5%	$207.96M	$19.39M	N/A	50	News Coverage Insider Trade Gap Up
DRCT Direct Digital	0.5025 of 5 stars	$2.71 +2.7%	N/A	-98.0%	$2.01M	$33.22M	N/A	60	Negative News Analyst Forecast Gap Up
TRAW Traws Pharma	3.4025 of 5 stars	$0.84 +2.8%	$1.00 +18.6%	-46.3%	$8.57M	$2.79M	N/A	17	Gap Up
ESPR Esperion Therapeutics	3.0815 of 5 stars	$3.16 +0.3%	$5.54 +75.3%	+169.9%	$814.30M	$403.14M	N/A	200
OCS Oculis	3.5428 of 5 stars	$13.87 +6.0%	$38.33 +176.4%	-25.5%	$804.18M	$1.45M	N/A	2	News Coverage Positive News Short Interest Increase Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLGL) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sol-Gel Technologies (SLGL) Competitors

SLGL vs. DRCT, TRAW, ESPR, OCS, and SPRY

How does Sol-Gel Technologies compare to Direct Digital?

Summary

How does Sol-Gel Technologies compare to Traws Pharma?

Summary

How does Sol-Gel Technologies compare to Esperion Therapeutics?

Summary

How does Sol-Gel Technologies compare to Oculis?

Summary

How does Sol-Gel Technologies compare to ARS Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLGL vs. The Competition

Sol-Gel Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sol-Gel Technologies (SLGL) Competitors

SLGL vs. DRCT, TRAW, ESPR, OCS, and SPRY

How does Sol-Gel Technologies compare to Direct Digital?

Which has better earnings & valuation, DRCT or SLGL?

Is DRCT or SLGL more profitable?

Which has more volatility & risk, DRCT or SLGL?

Do analysts prefer DRCT or SLGL?

Do insiders & institutionals have more ownership in DRCT or SLGL?

Does the media refer more to DRCT or SLGL?

Summary

How does Sol-Gel Technologies compare to Traws Pharma?

Do analysts rate TRAW or SLGL?

Which has more risk & volatility, TRAW or SLGL?

Is TRAW or SLGL more profitable?

Which has higher valuation and earnings, TRAW or SLGL?

Do insiders and institutionals have more ownership in TRAW or SLGL?

Does the media favor TRAW or SLGL?

Summary

How does Sol-Gel Technologies compare to Esperion Therapeutics?

Which has higher earnings & valuation, SLGL or ESPR?

Is SLGL or ESPR more profitable?

Do analysts prefer SLGL or ESPR?

Do institutionals and insiders hold more shares of SLGL or ESPR?

Which has more risk & volatility, SLGL or ESPR?

Does the media favor SLGL or ESPR?

Summary

How does Sol-Gel Technologies compare to Oculis?

Does the media prefer SLGL or OCS?

Which has preferable earnings & valuation, SLGL or OCS?

Which has more risk & volatility, SLGL or OCS?

Do analysts rate SLGL or OCS?

Is SLGL or OCS more profitable?

Do insiders and institutionals believe in SLGL or OCS?

Summary

How does Sol-Gel Technologies compare to ARS Pharmaceuticals?

Which has more risk and volatility, SLGL or SPRY?

Does the media refer more to SLGL or SPRY?

Which has higher earnings & valuation, SLGL or SPRY?

Do analysts rate SLGL or SPRY?

Do insiders & institutionals believe in SLGL or SPRY?

Is SLGL or SPRY more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLGL vs. The Competition

Sol-Gel Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools